Online inquiry

IVTScrip™ mRNA-Anti-GPC3, GC33(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7555MR)

This product GTTS-WQ7555MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets GPC3 gene. The antibody can be applied in Hepatocellular carcinoma (HCC) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001164617.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2719
UniProt ID P51654
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GPC3, GC33(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ7555MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ7632MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN1029(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GEN1029
GTTS-WQ11658MR IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MHAA4549A
GTTS-WQ9637MR IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA JNJ-64007957
GTTS-WQ2544MR IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG 477
GTTS-WQ6020MR IVTScrip™ mRNA-Anti-IL12B, CNTO 1275(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CNTO 1275
GTTS-WQ15793MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA XmAb-13676
GTTS-WQ2076MR IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AIN457
GTTS-WQ10896MR IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MABp1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW